WOS: 000242137900010PubMed ID: 17072271The aim of this study was to compare the efficacy of a standard hepatitis B virus vaccination program (day 0-30-60) with an accelerated vaccination program (day 0-10-21) in healthy healthcare workers. Participants were randomly assigned to a classical (group 1, days 0, 30, and 60) or an accelerated vaccination program (group 2, days 0, 10, and 21). The vaccine used was 20 mu g recombinant hepatitis B vaccine (recombinant hepatitis B vaccine derived from yeast cells, Engerix B, Smith Cline Beachum). HBV markers were re-examined for the emergence of anti-HBsAg and also to detect the development of a possible acute HBV infection one, two, and three months after the last dose of vaccine. Anti-HBsAg titers > 10 mIU/1 were accepted as protective. The seroprotection rates were similar one, two, and three months after the last dose of vaccine in both groups. Anti-HBsAg titers in group 1 were higher than in group 2 two and three months after the last dose of vaccination (p < 0.05). Our data indicate that the accelerated HBV vaccination program was as effective as the classical vaccination program
